- Article
- OPEN ACCESS
-
Explore potential biomarkers to provide a theoretical basis for the treatment of liver fibrosis with pirfenidone
-
Hao Li1,
-
Xi-Yang Dong1,
-
Qin Zhou2,
-
Zhi-Xiang Ding1,
-
Qing-Hai Wang1 and
-
De-Hui Li1,*
Author information
Department of Infectious Diseases, The First People's Hospital of Changde City, Changde 415000, China
Intensive Care Unit, The First People's Hospital of Changde City, Changde 415000, China
Correspondence to: De-Hui Li, Department of Infectious Diseases, The First People's Hospital of Changde City, Changde 415000, China. E-mail:
lidehui0736@163.com
Abstract
Background
Hepatic fibrosis is a common chronic liver disease in clinic, the purpose of our study is to explore potential biomarkers to provide a theoretical basis for the treatment of liver fibrosis with pirfenidone.
Methods
We downloaded a gene-sequencing dataset and a single-cell dataset from the GEO database and pirfenidone target genes from three different databases. First, we performed GO, KEGG, and DO analysis on pirfenidone target genes. Then, we grouped the liver tissue sequencing data (GSE162694) in the sequencing data set (N-F0 group and F1-F4 group) and performed gene expression differential analysis on these two groups, weighted gene co-expression network analysis and gene Enrichment analysis. Finally, we intersected the significantly upregulated genes in the F1-F4 group with the pirfenidone target genes and performed PPI network analysis. In order to further explore the expression of both pirfenidone drug target genes and liver fibrosis disease genes (PDLFG) in different immune cells of liver tissue, we used the CD45+ cell data in the GSE136103 data set for further analysis.
Results
A subnetwork consisting of CDC42, HNF4A, BHLHE40, CCDC71L, NR1H3, TNF, MGLL, GPT, SCD and PLIN1 was screened out, and by analysis, we finally identified the SCD as PDLFG. In single-cell sequencing analysis, we found that SCD was highly expressed in M2-polarized macrophages.
Conclusion
SCD may be an important target protein to inhibit the progression of liver fibrosis.
Keywords
hepatic fibrosis,
pirfenidone target genes,
biomarker,
GSEA,
WGCNA,
single cell sequencing analysis
|
Copyright © 2025 Authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
About this Article
Cite this article
|
Li H, Dong XY, Zhou Q, Ding ZX, Wang QH, Li DH. Explore potential biomarkers to provide a theoretical basis for the treatment of liver fibrosis with pirfenidone. Gastroenterol & Hepatol Res. 2023;5(3):11. doi: 10.53388/ghr2023-03-075.
|
| Copied to clipboard
|
Copy
Export to RIS
Export to EndNote
|
|
Citation copied!
|
Article History
| Received |
Revised |
Accepted |
Published |
|
|
|
|
September 19, 2023
|
DOI
http://dx.doi.org/10.53388/ghr2023-03-075
-
Gastroenterology & Hepatology Research
-
-
eISSN 2703-173X